Your browser doesn't support javascript.
loading
Risk factors for permanent pacemaker implantation in patients receiving a balloon-expandable transcatheter aortic valve prosthesis.
Droppa, Michal; Rudolph, Tanja K; Baan, Jan; Nielsen, Niels-Erik; Baumgartner, Helmut; Vendrik, Jeroen; Froehlich, Maren; Borst, Oliver; Wöhrle, Jochen; Gawaz, Meinrad; Potratz, Paul; Hack, Luis P; Mauri, Victor; Baranowski, Jacek; Bramlage, Peter; Kurucova, Jana; Thoenes, Martin; Rottbauer, Wolfgang; Geisler, Tobias.
Afiliação
  • Droppa M; Department of Cardiology and Angiology, University Hospital of Tübingen, Tübingen, Germany.
  • Rudolph TK; Department of Cardiology, Heart Center, Cologne University, Cologne, Germany.
  • Baan J; Heart and Diabetes Center NRW, Ruhr University Bochum, Bad Oeynhausen, Germany.
  • Nielsen NE; Heart Center, Academic Medical Center, Amsterdam University, Amsterdam, Netherlands.
  • Baumgartner H; Department of Cardiology, Linköping University Hospital, Linköping, Sweden.
  • Vendrik J; Department of Cardiology III: Adult Congenital and Valvular Heart Disease, University Hospital Münster, Münster, Germany.
  • Froehlich M; Heart Center, Academic Medical Center, Amsterdam University, Amsterdam, Netherlands.
  • Borst O; Institute for Pharmacology and Preventive Medicine, Cloppenburg, Germany.
  • Wöhrle J; Department of Cardiology and Angiology, University Hospital of Tübingen, Tübingen, Germany.
  • Gawaz M; Department of Internal Medicine II, Cardiology, Angiology, Pulmonology, Intensive Care Medicine, University of Ulm, Ulm, Germany.
  • Potratz P; Department of Cardiology and Angiology, University Hospital of Tübingen, Tübingen, Germany.
  • Hack LP; Department of Cardiology and Angiology, University Hospital of Tübingen, Tübingen, Germany.
  • Mauri V; Department of Cardiology and Angiology, University Hospital of Tübingen, Tübingen, Germany.
  • Baranowski J; Department of Cardiology, Heart Center, Cologne University, Cologne, Germany.
  • Bramlage P; Department of Cardiology, Linköping University Hospital, Linköping, Sweden.
  • Kurucova J; Institute for Pharmacology and Preventive Medicine, Cloppenburg, Germany.
  • Thoenes M; Edwards Lifesciences, Prague, Czech Republic.
  • Rottbauer W; Edwards Lifesciences, Nyon, Switzerland.
  • Geisler T; Department of Internal Medicine II, Cardiology, Angiology, Pulmonology, Intensive Care Medicine, University of Ulm, Ulm, Germany.
Heart Vessels ; 35(12): 1735-1745, 2020 Dec.
Article em En | MEDLINE | ID: mdl-32591894
ABSTRACT
Permanent pacemaker implantation (PPI) is a widely recognized complication associated with TAVI (incidence up to 20%). Smaller registries have identified several variables associated with PPI. The objective was to validate patient- and transcatheter aortic valve implantation (TAVI)-related procedural variables associated with PPI. We performed a retrospective analysis of patients from six European centers undergoing TAVI with the Edwards SAPIEN 3 prosthesis. Baseline variables and pre-procedural ECG characteristics and CT-scans were taken into account. Data for 1745 patients were collected; 191 (10.9%) required PPI after TAVI. The baseline variables pulmonary hypertension (OR 1.64; 95% CI 1.01-2.59), QRS duration > 117 ms (OR 2.58; 95% CI 1.73-3.84), right bundle branch block (RBBB; OR 5.14; 95% CI 3.39-7.72), left anterior hemi block (OR 1.92; 95% CI 1.19-3.02) and first-degree atrioventricular block (AVB, OR 1.63; 95%CI 1.05-2.46) were significantly associated with PPI. RBBB (OR 8.11; 95% CI 3.19-21.86) and first-degree AVB (OR 2.39; 95% CI 1.18-4.66) remained significantly associated in a multivariate analysis. Procedure-related variables included access site (TF; OR 1.97; 95% CI 1.07-4.05), implanted valve size (29 mm; OR 1.88; 95% CI 1.35-2.59), mean TAVI valve implantation depth below the annulus > 30% (OR 3.75; 95% CI 2.01-6.98). Patients receiving PPI had longer ICU stays and later discharges. Acute kidney injury stage 2/3 was more common in patients with PPI until discharge (15.2 vs. 3.1%; p = 0.007), but was not statistically significant thereafter. Further differences in outcomes at 30 days did not reach significance. The data will aid pre- and post-procedural patient management and prevent adverse long-term outcomes.Clinical Trial NCT03497611.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Diagnostic_studies / Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Aged / Aged80 / Female / Humans / Male País/Região como assunto: Europa Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Diagnostic_studies / Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Aged / Aged80 / Female / Humans / Male País/Região como assunto: Europa Idioma: En Ano de publicação: 2020 Tipo de documento: Article